Fig. 1 · Structure

Documents & Downloads

Selinexor (KPT-330)

Cat. No. A12582 CAS 1393477-72-9

CRM1 inhibitor

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.

In Stock

Publications for Selinexor

4 publications citing this product

  1. Yingying Gao, .et al. , Am J Physiol Renal Physiol, 2025, Oct 1;329(4):F496-F509 PMID: 40897473
  2. Suhyun Lee, .et al. , Pharmaceutics, 2025, Jul 16;17(7):919 PMID: 40733127
  3. Youjin Na, .et al. , Oncogene, 2023, Mar;42(13):1038-1047 PMID: 36759572
  4. Chie Ishikawa, .et al. , Invest New Drugs, 2022, Aug;40(4):718-727 PMID: 35477814

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Selinexor (KPT-330) inhibits XPO1-mediated nuclear export. In Jurkat cells, it increased nuclear RanBP1 accumulation, whereas XPO1 C528S comparators showed little response, supporting target-dependent activity in this cellular model. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
CRM1 (Cell-free assay)

Selinexor (KPT-330) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Selinexor (KPT-330) from 2 published references. In vivo models include five TNBC PDX models in female BALB/c nu/nu mice.

Selinexor (KPT-330) In Vitro Studies

In a 72-hour leukemia-cell viability assay, wild-type Jurkat cells had a selinexor EC50 of 53.15 ± 3.6 nM. XPO1 C528S comparators were less sensitive. These engineered-cell findings identify a limit to response and do not establish the clinical prevalence of this mechanism. [1]

Across 26 breast cancer cell lines, selinexor inhibited growth with a reported median IC50 of 66 nM after 72 hours. Responses varied: the TNBC median was 44 nM, while the ER-positive median exceeded 1000 nM. These values describe an SRB growth assay. [2]

XPO1-dependent nuclear export in Jurkat cells

Cell-based study · Jurkat leukemia cells: parental XPO1 WT/WT, WT/C528S and C528S/C528S comparators. [1]

After 3 hours, selinexor caused nuclear accumulation of RanBP1 in wild-type cells; the C528S comparators showed little response. This functional cellular assay supports XPO1 target dependence, rather than a purified-protein binding constant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RanBP1 nuclear/cytoplasmic localizationQualitative response Nuclear accumulation in wild-type cells at 3 μM; localization largely unaffected in heterozygous and homozygous C528S comparators.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Dilution series; representative imaging at 3 μM.
Exposure duration
3 hours
Method
RanBP1 immunostaining; nuclear/cytoplasmic signal quantified by high-content imaging.
Vehicle
DMSO carrier control
Co-treatment
Single-agent selinexor.
Reported limits
Exact full dilution series is not transcribed from the plotted axis; no binding affinity measured.
Methods and source locations

Compound reported in the paper: Selinexor (KPT-330); Compound label in the paper: KPT-330 / selinexor

Evidence concerns the named compound in the reported models. Paper material is not an analytical validation of Adooq SKU A12582, its current lot or stereochemical purity.

Figure 2B–C; Results, Heterozygous substitution...; Methods, High content imaging of RanBP1

RanBP1 nuclear/cytoplasmic localization: Figure 2B–C; mean ± SD, N=2 for quantification; Results state at least 200 cells analyzed per condition. Cells are not independent biological replicates. — Figure 2B–C and caption; Results paragraph beginning To confirm...

Selinexor sensitivity in wild-type and C528S leukemia cells

Cell-based study · HL-60, Jurkat and K-562 parental and XPO1 C528S comparator cell lines. [1]

Wild-type cells had nanomolar viability EC50 values, whereas C528S comparators had markedly higher EC50 values. Heterozygous mutation was sufficient for reduced sensitivity in these engineered cancer-cell models.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HL-60 viability relative to DMSOEC50 (nM) XPO1 WT/WT: 125.8 ± 22.5; WT/C528S: 12,683 ± 3,006; C528S/C528S: 12,364 ±6,360.[1]
Jurkat viability relative to DMSOEC50 (nM) XPO1 WT/WT: 53.15 ± 3.6; WT/C528S: 6,490 ± 2,582; C528S/C528S: 16,987 ± 1,052.[1]
K-562 viability relative to DMSOEC50 (nM) XPO1 WT/WT: 183.7 ± 26.2; WT/C528S: 55,360 ± 13,836; C528S/C528S: 38,575 ± 5,048.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Serial KPT-330 dilutions; EC50 values below are assay endpoints, not treatment concentrations.
Exposure duration
72 hours
Method
CellTiter 96 AQueous viability readout normalized to DMSO.
Vehicle
DMSO
Co-treatment
Single-agent selinexor.
Reported limits
Full concentration schedule not transcribed; final DMSO percentage and compound purity not stated in the reviewed assay section.
Methods and source locations

Compound reported in the paper: Selinexor (KPT-330); Compound label in the paper: KPT-330 / selinexor

Evidence concerns the named compound in the reported models. Paper material is not an analytical validation of Adooq SKU A12582, its current lot or stereochemical purity.

Table 2; Figure 2A; Methods, Cell viability assays; Figure 1G and related Results

HL-60 viability relative to DMSO: 72-hour CellTiter 96 AQueous assay, absorbance at 490 nm; four-parameter log model. Table 2 does not separately define its ± term. Figure 2A shows mean ± SD (N=3 duplicates); Methods: duplicate assays repeated at least three times. — Table 2, HL-60 row; Figure 2A caption; Methods, Cell viability assays

Jurkat viability relative to DMSO: 72-hour CellTiter 96 AQueous assay, absorbance at 490 nm; four-parameter log model. Table 2 does not separately define its ± term. Figure 2A shows mean ± SD (N=3 duplicates); Methods: duplicate assays repeated at least three times. — Table 2, Jurkat row; Figure 2A caption; Methods, Cell viability assays

K-562 viability relative to DMSO: 72-hour CellTiter 96 AQueous assay, absorbance at 490 nm; four-parameter log model. Table 2 does not separately define its ± term. Figure 2A shows mean ± SD (N=3 duplicates); Methods: duplicate assays repeated at least three times. — Table 2, K-562 row; Figure 2A caption; Methods, Cell viability assays

Breast cancer cell growth panel

Cell-based study · Twenty-six breast cancer cell lines, including 14 triple-negative breast cancer (TNBC) lines and ER-positive and HER2-positive models. [2]

Growth inhibition varied across the panel. The reported TNBC median IC50 was lower than the ER-positive median, with some ER-positive lines exceeding 1000 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Growth inhibition in the 26-line panelIC50 (nM) Overall median 66 (range 11 to >1000); TNBC median 44 (range 11 to 550); ER-positive median >1000 (range 40 to >1000); reported TNBC versus ER-positive P=0.017.[2]

Literature-Reported Treatment Conditions

Treatment concentration
Ten concentrations based on a fivefold dilution series; reported range 0–100 μM.
Exposure duration
72 hours
Method
Sulforhodamine B (SRB) growth assay; dose-response IC50 estimation.
Vehicle
DMSO
Co-treatment
Single-agent selinexor.
Reported limits
Final DMSO percentage not stated in the reviewed proliferation method. IC50 values are growth assay endpoints.
Methods and source locations

Compound reported in the paper: Selinexor (KPT-330); Compound label in the paper: KPT-330 / selinexor

Evidence concerns the named compound in the reported models. Paper material is not an analytical validation of Adooq SKU A12582, its current lot or stereochemical purity.

Figure 1 and caption; Results, Selinexor has potent antitumor efficacy...; Methods, Cell proliferation assays and Drugs and reagents

Growth inhibition in the 26-line panel: SRB after 72 hours; triplicate wells; experiments performed at least three times. Aggregate medians/ranges are those reported in main Results; no ± is attached to these summaries. — Results, Selinexor has potent antitumor efficacy... first paragraph; Figure 1; Methods, Cell proliferation assays

Selinexor (KPT-330) In Vivo Studies

Oral selinexor reduced tumor growth significantly in four of five TNBC patient-derived xenograft models; BCX51 showed no significant effect. At 12.5 mg/kg twice weekly, the reported median treatment/control tumor-volume ratio was 42% (range 31–73%). This model-dependent response should be distinguished from the paper’s activity cutoff of T/C <40%. [2]

TNBC patient-derived xenograft monotherapy

Animal study · Five TNBC PDX models in female BALB/c nu/nu mice. [2]

Selinexor reduced tumor growth significantly in four of five models, with no significant effect in BCX51. The reported median T/C ratio was 42%; statistical significance and the study-defined activity cutoff of T/C <40% are different criteria.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative tumor growth versus matched vehicleT/C ratio (%) Reported median 42% (range 31–73%); activity defined as T/C <40%.[2]
Model-specific tumor growth comparisonSignificance BCX6 P<0.0001; BCX10 P<0.0002; BCX11 P<0.0001; BCX22 P<0.0009; BCX51 NS.[2]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Twice weekly
Treatment course
2 weeks on, 1 week off; total number of cycles not specified for the Figure 4 monotherapy comparison.
Vehicle
0.6% w/v Pluronic F-68 surfactant and 0.6% w/v PVP K-29/32 polymer.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Selinexor monotherapy across five TNBC PDX models
12.5 mg/kg
Matched vehicle-treated tumor-bearing mice in each PDX model.Tumor growth was significantly lower in BCX6, BCX10, BCX11 and BCX22; BCX51 was nonsignificant. Reported median T/C ratio 42% (range 31–73%).[2]
Selinexor monotherapy across five TNBC PDX models
Model: BCX6, BCX10, BCX11, BCX22 and BCX51 in female BALB/c nu/nu mice (6–8 weeks old at implantation).
Reported limits: Group sizes, allocation randomization and blinding are not stated in the reviewed main Methods/Figure 4 caption. No fixed dosing course is inferred from time-axis endpoints.
Methods and source locations

Compound reported in the paper: Selinexor (KPT-330); Compound label in the paper: KPT-330 / selinexor

Evidence concerns the named compound in the reported models. Paper material is not an analytical validation of Adooq SKU A12582, its current lot or stereochemical purity.

Figure 4 and caption; Results, Selinexor has in vivo efficacy...; Methods, In vivo studies and Drugs and reagents

Relative tumor growth versus matched vehicle: T/C = (median treated tumor volume / median control tumor volume) ×100. Figure 4 time-course values are mean ± SEM; endpoint comparisons analyzed by two-way ANOVA per caption. Exact model-wise bar values were not read off curves. — Results, Selinexor has in vivo efficacy... first paragraph; Figure 4 caption

Model-specific tumor growth comparison: Operators and model labels transcribed from viewed Figure 4. NS means nonsignificant, not proven equivalence. — Figure 4 model-panel annotations

Selinexor monotherapy across five TNBC PDX models · Figure 4 and caption; Results, Selinexor has in vivo efficacy... first paragraph; Methods, In vivo studies and Drugs and reagents

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1393477-72-9
Applications CRM1 inhibitor
Formula C17H11F6N7O
Molecular Weight 443.31
Synonyms KPT330
SMILES
C1=CN=C(C=N1)NNC(=O)/C=C\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 78 mg/mL (175.94 mM)
Water Insoluble
Ethanol 36 mg/mL (81.21 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
3 mg/mL
Vehicle
2% DMSO+40%PEG 300+5% Tween80 +ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Selinexor (KPT-330) Research References

  1. [1] Neggers JE, Vanstreels E, Baloglu E, et al. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export. Oncotarget (2016). PMID: 27634897 DOI: 10.18632/oncotarget.11995 Source material
  2. [2] Arango NP, Yuca E, Zhao M, et al. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast cancer research : BCR (2017). PMID: 28810913 DOI: 10.1186/s13058-017-0878-6 Source material

Publications

4 publications citing this product

  1. Yingying Gao, .et al. , Am J Physiol Renal Physiol, 2025, Oct 1;329(4):F496-F509 PMID: 40897473
  2. Suhyun Lee, .et al. , Pharmaceutics, 2025, Jul 16;17(7):919 PMID: 40733127
  3. Youjin Na, .et al. , Oncogene, 2023, Mar;42(13):1038-1047 PMID: 36759572
  4. Chie Ishikawa, .et al. , Invest New Drugs, 2022, Aug;40(4):718-727 PMID: 35477814

Added to your cart

View Cart Checkout
Loading...